Reuters logo
Fitch Rates Express Scripts Bank Facility 'BBB'; CP Program 'F2'
November 1, 2017 / 6:08 PM / a month ago

Fitch Rates Express Scripts Bank Facility 'BBB'; CP Program 'F2'

(The following statement was released by the rating agency) CHICAGO, November 01 (Fitch) Fitch Ratings has assigned a 'BBB' rating to Express Scripts Holding Company's $6.125 billion senior unsecured bank facility. Fitch has also assigned an 'F2' CP rating and an 'F2' Short-Term Issuer Default Rating (IDR) to Express Scripts. In addition, Fitch has affirmed the existing ratings, including the 'BBB' IDR. A full list of rating actions follows at the end of this release. The ratings apply to approximately $17.8 billion of debt pro forma as of Sept. 30, 2017. The Rating Outlook is Stable. KEY RATING DRIVERS Market-Leading Scale: The ratings reflect the company's market-leading scale and strong cash flows on stable margins and efficient working capital. ESRX is the largest stand-alone pharmacy benefit manager (PBM) and one of the largest pharmacy operators in the U.S. Fitch expects such scale to continue enabling ESRX to negotiate favorable purchasing discounts and pricing rebates and to leverage its fixed costs associated with mail-order pharmacy. These positives are offset by Express Script's leveraged acquisition strategy, increased competition and the expected loss of earnings as well as pending litigation with Anthem, Inc. Strong Cash Flows: Despite relatively low margins (as reported), ESRX exhibits consistent and robust cash flows, which are driven by excellent working capital management and very efficient operations. Consistent cash flows and a solid liquidity profile afford good ratings flexibility at current ratings in the event of acquisitions, such as the proposed acquisition of eviCore, a medical benefits manager, for $3.6 billion in cash. FCF to adjusted debt for the TTM ended June 30, 2017 was approximately 35%. Historically an Active Acquirer: ESRX has been an active acquirer over the past decade, often employing large debt balances to fund deals. The possibility of large-scale M&A and a significant increase in leverage pressure the ratings somewhat. Notably, the firm has routinely executed on its de-leveraging plans, reducing leverage appropriately within 12-18 months of each deal. Total debt to operating EBITDA was approximately 2x for the TTM ended June 30, 2017. Increasing Competition, Consolidation: ESRX is expected to continue to experience pricing pressure from new contracts, consolidating clients and competitors, including the potential for competition from non-traditional players. Current trends supporting consolidation and alignment in many areas of healthcare are expected to continue for the foreseeable future. Growth Opportunities: Fitch believes ESRX will continue to grow, albeit at low-single-digit levels because of its scale, specialty-market growth, the emergence of biosimilar drugs, and ongoing cost containment efforts by payors. These forces are expected to produce increased PBM volumes and utilization of more value-added services. In addition, ESRX is uniquely positioned to leverage data about patient outcomes in order to help improve the effectiveness of treatments and to lower costs. Loss of Anthem Business: Fitch's ratings case forecast for ESRX assumes the company loses about $20 billion of revenue associated with its contract with health insurer Anthem in 2019-2020. While the loss of the Anthem contract is absorbable at the current rating level, if customer retention ultimately requires increased pricing concessions, it could eat further into ESRX's margins over the longer term as contracts roll. If this constrains ESRX's ability to maintain leverage at or below 2.3x, it may result in a negative rating action. While Anthem's dispute with ESRX comes down to a pricing dispute with one customer, it is occurring at the same time that other PBM customers are expressing concerns about the industry's pricing model. DERIVATION SUMMARY Express Scripts' BBB IDR reflects the company's strong position as the largest stand-alone PBM company in the U.S., moderate leverage and consistent FCF generation. Express Scripts stand-alone profile differs from its two leading peers: CVSCaremark (owned by CVS Health - not rated) and OptumRx (owned by UnitedHealthGroup - A/Stable), and as a result, raises the potential for greater concentration risk of its revenue stream. ESRX's scale and size of its operations (measured by claims processed) provides strong negotiating leverage with manufacturers and pharmacies, which supports steady cash flows compared with smaller peers such as MedImpact (BB-/Positive), and other PBMs owned by managed care organizations such as Aetna and Humana. Express Scripts is rated at or below some other healthcare and life science entities, such as Agilent Technologies, Inc. (BBB+/Stable) and PerkinElmer (BBB/Stable) even though its FCF as a percentage of debt is substantially higher because of its growth strategy based on acquisitions and record of significant share repurchases. KEY ASSUMPTIONS Fitch's key assumptions within our rating case for the issuer include: --Annual revenue growth of 3% in 2018-2020 for the core business ex-Anthem. Assume the Anthem contract terminates leading to a loss of approximately $20 billion of revenue over 2019-2020; --Total debt of approximately $17 billion at the end of 2017, pro forma for the acquisition of eviCore; --Gross debt/EBITDA between 2.0x-2.3x through 2020, this assumption incorporates repayment of all maturing debt during the forecast period; --Strong FCF between $4.5 billion-$5 billion in 2017-2019, directed toward acquisitions, shareholder payouts and mandatory debt repayment; upon loss of the Anthem business in 2020 FCF is maintained near $3 billion. RATING SENSITIVITIES Future Developments That May, Individually or Collectively, Lead to Positive Rating Action -ESRX's current 'BBB' ratings contemplates gross debt/EBITDA of around 2.3x over the forecast period. With the amendment to the bank credit facility and addition of a CP program, ESRX will have more flexibility to manage working capital needs and small acquisitions. Positive rating actions are unlikely over the near to medium term without a shift in ESRX's financial policy that results in debt to EBITDA durably below 1.5x. Future Developments That May, Individually or Collectively, Lead to Negative Rating Action -A downgrade could result if Fitch expects debt/EBITDA will remain above 2.3x over the rating horizon and that FCF deteriorates beyond the levels caused by the loss of the Anthem contract. This development might result from any or a combination of the following factors: a significant, leveraged acquisition, prolonged negative underlying script growth, customer losses, or heightened competition. LIQUIDITY Solid Liquidity: The rating action follows Express Script's recent announcement of an amended and restated $6.125 billion bank credit agreement and the creation of a $3.5 billion CP program, both of which are expected to be partially used to finance ESRX's proposed $3.6 billion acquisition of eviCore. Fitch believes ESRX has a solid liquidity profile, supported by approximately $2 billion of cash and equivalents over the forecast period, the $3.5 billion CP program, and availability of a revolving credit facility under the amended and restated credit facility of $3.5 billion (due October 2022). Fitch understands that Express Scripts will maintain 100% revolver coverage for CP balance outstanding. Strong Cash Flows: Fitch estimates ESRX will have annualized FCF over the forecast period of approximately $4.5 billion. Strong cash flows are driven by good customer retention, excellent working capital management and steady and efficient operations. Well-Laddered, Manageable Maturities: The firm's debt maturity schedule is well-laddered and manageable, especially given its strong cash flow profile. No more than approximately $2.5 billion is due for mandatory repayments through 2019, compared to annual forecasted FCF of $4.5 billion. Nevertheless, Fitch expects ESRX to pay down most debt maturities through 2019 and to direct the remainder of FCF toward M&A and share purchases. FULL LIST OF RATING ACTIONS Fitch has taken the following rating actions: Express Scripts Holding Company --Assign long-term senior unsecured bank facility rating of 'BBB'; --Assign Short-Term IDR of 'F2'; --Assign commercial paper rating of 'F2'. --Long-Term IDR affirmed at 'BBB'; --Senior unsecured notes affirmed at 'BBB'. Express Scripts, Inc. --Assign IDR of 'BBB' --Senior unsecured notes affirmed at 'BBB'. Medco Health Solutions, Inc. --Assign IDR of 'BBB'. --Senior unsecured notes affirmed at 'BBB'. The Rating Outlook is Stable. Contact: Primary Analyst Patrick Finnegan, CFA Senior Director +1 646-582-4620 Fitch Ratings, Inc. 33 Whitehall Street New York, NY 10004 Bob Kirby, CFA Director +1-312-368-3147 Committee Chairperson Megan Neuburger, CFA Managing Director +1-212-908-0501 Summary of Financial Statement Adjustments Historical and projected EBITDA is adjusted to add back non-cash stock-based compensation; Historical revenue amounts have been adjusted to eliminate amortization expense related to the Anthem contract and to reclassify such amounts as amortization expense; Historical provision for income taxes adjusted for the deemed one-time tax benefits related to the PolyMedica Corporation tax and various state tax audit settlements. Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email: alyssa.castelli@fitchratings.com. Additional information is available on www.fitchratings.com Applicable Criteria Corporate Rating Criteria (pub. 07 Aug 2017) here Non-Financial Corporates Notching and Recovery Ratings Criteria (pub. 16 Jun 2017) here Parent and Subsidiary Rating Linkage (pub. 31 Aug 2016) here Additional Disclosures Dodd-Frank Rating Information Disclosure Form here Solicitation Status here#solicitation Endorsement Policy here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: here. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEB SITE AT WWW.FITCHRATINGS.COM. PUBLISHED RATINGS, CRITERIA, AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE, AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF CONDUCT SECTION OF THIS SITE. DIRECTORS AND SHAREHOLDERS RELEVANT INTERESTS ARE AVAILABLE here. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE. Copyright © 2017 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch’s factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third- party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch’s ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed. The information in this report is provided “as is” without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US$1,000 to US$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US$10,000 to US$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers. For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below